214 related articles for article (PubMed ID: 32880206)
1. Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1.
Lu JD; Milakovic M; Ortega-Loayza AG; Marzano AV; Alavi A
Expert Opin Investig Drugs; 2020 Nov; 29(11):1179-1185. PubMed ID: 32880206
[TBL] [Abstract][Full Text] [Related]
2. Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated With infliximab.
Groleau PF; Grossberg AL; Gaspari AA
Cutis; 2015 Jun; 95(6):337-42. PubMed ID: 26125210
[TBL] [Abstract][Full Text] [Related]
3. New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.
Yamanaka K
J Dermatol; 2024 Feb; 51(2):172-179. PubMed ID: 38009911
[TBL] [Abstract][Full Text] [Related]
4. Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne.
Vinkel C; Thomsen SF
Int J Dermatol; 2017 Aug; 56(8):811-818. PubMed ID: 28345207
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of diseases associated with pyoderma gangrenosum and correlation with effectiveness of therapy: New insights on the diagnosis and therapy of comorbid hidradenitis suppurativa.
Fischer AH; Jourabchi N; Khalifian S; Lazarus GS
Wound Repair Regen; 2022 May; 30(3):338-344. PubMed ID: 35385180
[TBL] [Abstract][Full Text] [Related]
6. Pyoderma gangrenosum: A systematic review of the molecular characteristics of disease.
Flora A; Kozera E; Frew JW
Exp Dermatol; 2022 Apr; 31(4):498-515. PubMed ID: 35114021
[TBL] [Abstract][Full Text] [Related]
7. Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa.
Grand D; Navrazhina K; Frew JW
Exp Dermatol; 2020 Jan; 29(1):86-92. PubMed ID: 31688984
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab.
Reddick CL; Singh MN; Chalmers RJ
Dermatol Online J; 2010 Aug; 16(8):15. PubMed ID: 20804692
[TBL] [Abstract][Full Text] [Related]
9. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?
Kanni T; Zenker O; Habel M; Riedemann N; Giamarellos-Bourboulis EJ
Br J Dermatol; 2018 Aug; 179(2):413-419. PubMed ID: 29405257
[TBL] [Abstract][Full Text] [Related]
10. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review.
Hsiao JL; Antaya RJ; Berger T; Maurer T; Shinkai K; Leslie KS
Arch Dermatol; 2010 Nov; 146(11):1265-70. PubMed ID: 21079064
[TBL] [Abstract][Full Text] [Related]
11. Neutrophilic dermatosis and hidradenitis suppurativa in patients with Behçet's disease: A neutrophilic disease in the spectrum of autoinflammatory syndromes.
Bugaut H; Barete S; Bagot M; Bouaziz JD; Le Pelletier de Glatigny F; Gallien Y; Biard L; Domont F; Cacoub P; Saadoun D; Comarmond C
Semin Arthritis Rheum; 2023 Aug; 61():152224. PubMed ID: 37207416
[TBL] [Abstract][Full Text] [Related]
12. Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome: A Case Report and Literature Review.
Huang J; Tsang LS; Shi W; Li J
Front Med (Lausanne); 2022; 9():856786. PubMed ID: 35402426
[TBL] [Abstract][Full Text] [Related]
13. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
14. Pyoderma gangrenosum associated with hidradenitis suppurativa.
Ah-Weng A; Langtry JA; Velangi S; Evans CD; Douglas WS
Clin Exp Dermatol; 2005 Nov; 30(6):669-71. PubMed ID: 16197385
[TBL] [Abstract][Full Text] [Related]
15. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen.
Shenefelt PD
Cutis; 1996 May; 57(5):315-9. PubMed ID: 8726710
[TBL] [Abstract][Full Text] [Related]
16. Neutrophilic dermatoses: a review of current treatment options.
Cohen PR
Am J Clin Dermatol; 2009; 10(5):301-12. PubMed ID: 19658442
[TBL] [Abstract][Full Text] [Related]
17. Complement inhibition in ANCA vasculitis.
Jayne D
Nephrol Ther; 2019 Nov; 15(6):409-412. PubMed ID: 31631015
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin-responsive hidradenitis suppurativa.
Buckley DA; Rogers S
J R Soc Med; 1995 May; 88(5):289P-290P. PubMed ID: 7636825
[TBL] [Abstract][Full Text] [Related]
19. Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis.
Tada M; Nakanishi T; Hirata C; Okano T; Sugioka Y; Wakitani S; Nakamura H; Koike T
Mod Rheumatol; 2010 Dec; 20(6):598-601. PubMed ID: 20680379
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab.
Giamarellos-Bourboulis EJ; Argyropoulou M; Kanni T; Spyridopoulos T; Otto I; Zenker O; Guo R; Riedemann NC
Br J Dermatol; 2020 Jul; 183(1):176-178. PubMed ID: 31954061
[No Abstract] [Full Text] [Related]
[Next] [New Search]
